IntroductionThe aim of this study is to conduct a meta-analysis to assess the efficacy of yttrium-90 selective internal radiation therapy (SIRT) in treating patients with breast cancer with hepatic metastasis.MethodPubMed and The Cochrane Library were queried from establishment to January 2021. The following keywords were implemented: “breast”, “yttrium”, and “radioembolization”. The following variables and outcomes were collected: publication year, region, sample size, study design, presence of extrahepatic disease, tumor burden, infused radioactivity, breast cancer subtype, previous treatment, median survival time (MST), length of follow-up, adverse events, and radiographical response such as Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), and Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST).ResultsA total of 24 studies from 14 institutions were included in the present meta-analysis. On the basis of the data from 412 patients, post-embolization MST was 9.8 [95% confidence interval (CI): 9.0–11.6] months. Patients with additional extrahepatic metastasis had a poorer survival rate compared with those with localized hepatic metastasis only (MST: 5.3 vs. 15 months, p < 0.0001). Patients with <25% liver tumor burden exhibited more promising survival than those with >25% (MST: 10.5 vs. 6.8 months, p < 0.0139). On the basis of RECIST, mRECIST, and PERCIST criteria, tumor response rate was 36% (95% CI: 26%–47%), 49% (95% CI: 34%–65%), and 47% (95% CI: 17%–78%), respectively, whereas tumor control rate was 85% (95% CI: 76%–93%), 73% (95% CI: 59%–85%), and 97% (95% CI: 91%–100%), respectively.ConclusionOn the basis of the available published evidence, SIRT is feasible and effective in treating patients with breast cancer with liver metastasis. Patients with lower hepatic tumor burden and without extrahepatic metastasis demonstrated more survival benefit. Future randomized controlled trials are warranted.

atropine, morphine, and nitroglycerine, and the liberal use of oxygen gas, I had succeeded in lessening the severity and shortening the period to less than a week, but the results were much less satisfactory than when euphorbia was used, together with the above described combination subcutaneously. For hypodermatic use the follow¬ ing was employed: R-Morphinae sulphas, gr. 1-4.Atropinas sulphas, gr. 1-150.Trinitrin, gtt. 1. ttjj Sig. For subcutaneous use; for one dose.The formula adapted for the exhibition of euphorbia as follows: R-Ext. euphorbae pilulifera (P. D. & Co's.).Glycerini, ää fl. oz. ij. tt)> Sig. Take one teaspoonful every three hours.If those who have had experience with this remedy will kindly communicate the results of their observations to me, I will be glad to give them credit in the form of a collective report.

No abstract

In the final issue of MAR's inaugural year, we look at a collection of cases building on both recent trends and breaking new ground in the U.S. arbitration law. First, we review the Fifth Circuit's decision to stay away from compelling a party to pay its share of the arbitral costs and fees. In a down economy, the topic is particularly important. Second, we look at the effects of the sovereign immunity of the American Indian Tribes on an arbitration clause. It appears sovereign immunity can apply with equal force both domestically and internationally. Third, we go back to the Tenth Circuit to discuss the proper means for triggering appellate jurisdiction when moving the district court to compel arbitration. The answer is question of technicality and specificity in writing. Finally, we consider the latest in a line of cases on the future of manifest disregard. The Tenth Circuit is latest court to chime in by trying to dodge the question.

cinated' and 're-vaccinated' or 'doubly protected' with the death rate of only 89 per million among our mixed and for the most part 'unprotected' popula¬ tion at Leicester, and we may repeat : 'Wherein is